Tarsus Pharmaceuticals reports Q3 EPS ($1.28), consensus ($1.40)

Reports Q3 revenue $1.87M, consensus $0.72M. We are proud to be able to bring XDEMVY to the millions of people suffering from Demodex blepharitis, who, until recently, have been living without an effective, FDA-approved treatment option,” said Bobak Azamian, M.D., Ph.D., CEO and Chairman of Tarsus. “The XDEMVY launch is off to a strong start and we are encouraged by the early momentum among eye care providers and patients we have generated in just the first few weeks of availability.”